# OnCo record zynlonta (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zynlonta/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zynlonta" ;
  schema:name "Loncastuximab tesirine"@en ;
  schema:description "Loncastuximab tesirine (Zynlonta) is a CD19 ADC with a DNA-crosslinking payload for relapsed large B-cell lymphoma."@en ;
  schema:url <https://onco.cc/drugs/zynlonta/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Loncastuximab_tesirine> ;
  owl:sameAs <http://www.wikidata.org/entity/Q39057117> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Loncastuximab%20tesirine> ;
  onco:status "approved" ;
  onco:modality "ADC" ;
  schema:alternateName "Zynlonta" ;
  onco:approval "US 2021: Relapsed/refractory DLBCL after ≥2 systemic therapies", "EU 2022: R/R DLBCL ≥2 lines (conditional)" ;
  onco:acceleratedApproval "US 2021-04-23: Treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma." ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/adc-therapeutics/> ;
  onco:terms <https://onco.cc/terms/val-ala/> ;
  onco:trials <https://onco.cc/trials/nct04384484/>, <https://onco.cc/trials/nct05658562/> .